Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 6/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25245955 | 0.88 | GPR119 (0.48) | BCL2BCL2L1GPR119TBK1 | |
| SCHEMBL30459592 | 0.88 | GPR119 (0.48) | BCL2BCL2L1GPR119TBK1 | |
| SCHEMBL25245953 | 0.88 | GPR119 (0.48) | BCL2BCL2L1GPR119TBK1 | |
| SCHEMBL20578235 | 0.88 | BCL2 (0.41) | BCL2BCL2L1 | |
| SCHEMBL19692632 | 0.86 | BCL2 (0.54) | BCL2BCL2L1ALKMEN1MAPT | |
| SCHEMBL19708397 | 0.86 | BCL2 (0.51) | BCL2BCL2L1ALKMEN1MAPT | |
| SCHEMBL24982743 | 0.86 | BCL2 (0.46) | BCL2BCL2L1ALKMEN1MAPT | |
| SCHEMBL19692603 | 0.86 | BCL2 (0.55) | BCL2BCL2L1ALKMEN1MAPT | |
| SCHEMBL19839935 | 0.83 | BCL2 (0.52) | BCL2BCL2L1ALKMEN1MAPT | |
| SCHEMBL19708470 | 0.82 | BCL2 (0.38) | BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185471-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185471-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| EP-3468973-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | Dr. Reddy's Laboratories Ltd. (IN) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017212431-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY’S LABORATORIES LIMITED (IN) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017212431-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY’S LABORATORIES LIMITED (IN) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185471-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | MCL1, PROC, U2AF1 | BCL2 548/4885BCL2L1 856/4885GPR119 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.